Literature DB >> 19232227

Mumps outbreak among the military in Luxembourg in 2008: epidemiology and evaluation of control measures.

J Mossong1, C Bonert, P Weicherding, M Opp, P Reichert, J Even, F Schneider.   

Abstract

In the last quarter of 2008, an outbreak of mumps occurred in Luxembourg affecting initially 10 young adults at a military centre. Following a mass vaccination campaign, no further clinical cases were observed. 90% of 136 vaccine recipients were IgG positive one month after vaccination compared to 54% before vaccination. Until 31 December 2008, 19 mumps cases were also reported from the community. The outbreak strain belonged to genogroup G.

Mesh:

Year:  2009        PMID: 19232227

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  4 in total

1.  Seroepidemiology of mumps in Europe (1996-2008): why do outbreaks occur in highly vaccinated populations?

Authors:  J Eriksen; I Davidkin; G Kafatos; N Andrews; C Barbara; D Cohen; A Duks; A Griskevicius; K Johansen; K Bartha; B Kriz; G Mitis; J Mossong; A Nardone; D O'Flanagan; F DE Ory; A Pistol; H Theeten; K Prosenc; M Slacikova; R Pebody
Journal:  Epidemiol Infect       Date:  2012-06-12       Impact factor: 4.434

2.  Determinants of students' willingness to accept a measles-mumps-rubella booster vaccination during a mumps outbreak: a cross-sectional study.

Authors:  Hanna W Donkers; Jeannine L A Hautvast; Reinier P Akkermans; Corien M Swaan; Wilhelmina L M Ruijs; Marlies E J L Hulscher
Journal:  BMC Public Health       Date:  2015-06-20       Impact factor: 3.295

3.  Emerging and re-emerging infectious diseases: challenges and opportunities for militaries.

Authors:  Zheng Jie Marc Ho; Yi Fu Jeff Hwang; Jian Ming Vernon Lee
Journal:  Mil Med Res       Date:  2014-09-24

4.  Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity.

Authors:  Christina Poethko-Müller; Annette Mankertz
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.